Ceftaroline Fosamil: A Brief Clinical Review

被引：27
作者：
Shirley D.-A.T. [1 ]
Heil E.L. [2 ]
Johnson J.K. [3 ,4 ]
机构：
[1] Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore
[2] Department of Pharmacy, University of Maryland Medical Center, Baltimore
[3] Departments of Pathology and Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, 21201
[4] Microbiology and Virology Laboratories, University of Maryland Medical Center, Baltimore, MD, 21201
来源：
Infectious Diseases and Therapy | 2013年 / 2卷 / 2期
关键词：
Avibactam; Bacterial infection; Ceftaroline; Cephalosporin; Community-acquired infection; Methicillin-resistant S. aureus; Pneumonia; S; aureus; pneumoniae; Skin infection;
D O I：
10.1007/s40121-013-0010-x
中图分类号：
学科分类号：
摘要：
Ceftaroline is a novel cephalosporin with a favorable tolerability profile and broad in vitro activity against many resistant Gram-positive and common Gram-negative organisms. Ceftaroline fosamil is the first cephalosporin to be approved by the United States Food and Drug Administration (FDA) for the treatment of adults with acute bacterial skin and soft tissue infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It is also approved by the FDA for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae (with or without concurrent bacteremia), although there are no data at this time to support the use of ceftaroline fosamil for the treatment of pneumonia caused by MRSA. Ceftaroline fosamil is likewise approved by the European Commission for the treatment of adults with complicated skin and soft tissue infections or community-acquired pneumonia. This review summarizes the pharmacokinetic and microbiologic properties of ceftaroline, as well as the safety and efficacy data that led to its approval by the FDA in 2010 and the European Commission in 2012. Future directions to be addressed are also highlighted. © 2013 The Author(s).
引用
收藏
页码：95 / 110
页数：15
相关论文
共 92 条
[1]  
Boucher H.W., Talbot G.H., Bradley J.S., Et al., Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America, Clin Infect Dis, 48, pp. 1-12, (2009)
[2]  
The 10 × 20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020, Clin Infect Dis., 50, pp. 1081-1083, (2010)
[3]  
Nordberg P., Monnet D.L., Cars O., Antibacterial drug resistance [priority medicines for Europe and the world, a public health approach to innovation], (2004)
[4]  
European Centre for Disease Prevention and Control/European Medicines Agency Joint Technical Report, (2009)
[5]  
(2012)
[6]  
Iizawa Y., Nagai J., Ishikawa T., Et al., In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599, J Infect Chemother, 10, pp. 146-156, (2004)
[7]  
Jacqueline C., Caillon J., Batard E., Et al., Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model, J Antimicrob Chemother, 65, pp. 2264-2265, (2010)
[8]  
Jacqueline C., Caillon J., Le Mabecque V., Et al., In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin, Antimicrob Agents Chemother, 53, pp. 5300-5302, (2009)
[9]  
Jacqueline C., Caillon J., Le Mabecque V., Et al., In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model, Antimicrob Agents Chemother, 51, pp. 3397-3400, (2007)
[10]  
Croisier-Bertin D., Piroth L., Charles P.E., Et al., Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing, Antimicrob Agents Chemother, 55, pp. 3557-3563, (2011)
12345678910